Index NDX, S&P 500
P/E 103.83
EPS (ttm) 0.82
Insider Own 0.21%
Shs Outstand 1.25B
Perf Week 0.43%
Market Cap 105.76B
Forward P/E 11.75
EPS next Y 7.23
Insider Trans -2.59%
Shs Float 1.24B
Perf Month 2.15%
Income 1.05B
PEG 16.51
EPS next Q 1.55
Inst Own 84.86%
Short Float 1.43%
Perf Quarter 19.97%
Sales 27.78B
P/S 3.81
EPS this Y -43.73%
Inst Trans -0.06%
Short Ratio 2.72
Perf Half Y 24.80%
Book/sh 14.67
P/B 5.79
EPS next Y 91.14%
ROA 1.82%
Short Interest 17.74M
Perf Year 10.38%
Cash/sh 3.37
P/C 25.19
EPS next 5Y 6.29%
ROE 5.34%
52W Range 62.07 - 87.86
Perf YTD 4.86%
Dividend Est. 3.08 (3.62%)
P/FCF 15.34
EPS past 5Y 1.55%
ROI 2.64%
52W High -3.32%
Beta 0.20
Dividend TTM 3.06 (3.60%)
Quick Ratio 0.95
Sales past 5Y 4.16%
Gross Margin 77.60%
52W Low 36.86%
ATR (14) 1.39
Dividend Ex-Date Sep 13, 2024
Current Ratio 1.14
EPS Y/Y TTM -80.78%
Oper. Margin 36.44%
RSI (14) 62.61
Volatility 1.50% 1.55%
Employees 18000
Debt/Eq 1.28
Sales Y/Y TTM 2.05%
Profit Margin 3.79%
Recom 2.10
Target Price 86.64
Option/Short Yes / Yes
LT Debt/Eq 1.18
EPS Q/Q 55.31%
Payout 66.62%
Rel Volume 0.61
Prev Close 84.67
Sales Surprise 3.75%
EPS Surprise 25.05%
Sales Q/Q 5.46%
Earnings Nov 06 AMC
Avg Volume 6.51M
Price 84.95
SMA20 1.06%
SMA50 6.42%
SMA200 14.92%
Trades
Volume 3,982,287
Change 0.33%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-07-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$78 → $100
Jul-08-24 Upgrade
Raymond James
Mkt Perform → Outperform
$93
May-01-24 Reiterated
Maxim Group
Buy
$90 → $85
Apr-24-24 Upgrade
HSBC Securities
Reduce → Hold
$69
Feb-22-24 Downgrade
Truist
Buy → Hold
$91 → $82
Nov-09-23 Initiated
Deutsche Bank
Hold
$75
Sep-08-23 Upgrade
BofA Securities
Neutral → Buy
$88 → $95
Sep-06-23 Initiated
HSBC Securities
Reduce
$71
Jul-24-23 Reiterated
Barclays
Equal Weight
$81 → $80
May-16-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$90 → $100
Apr-28-23 Resumed
Piper Sandler
Overweight
$105
Jan-03-23 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$87
Dec-13-22 Resumed
BofA Securities
Neutral
$85
Dec-09-22 Downgrade
DZ Bank
Buy → Hold
$90
Oct-31-22 Upgrade
Barclays
Underweight → Equal Weight
$60 → $76
Oct-28-22 Upgrade
Truist
Hold → Buy
$76 → $91
Oct-28-22 Upgrade
Piper Sandler
Neutral → Overweight
$79 → $96
Oct-28-22 Reiterated
Wells Fargo
Equal Weight
$74 → $75
Oct-28-22 Reiterated
RBC Capital Mkts
Outperform
$79 → $82
Oct-28-22 Reiterated
JP Morgan
Overweight
$80 → $87
Show Previous Ratings
Oct-10-24 07:22PM
Oct-09-24 05:52PM
04:05PM
08:30AM
Oct-08-24 06:00PM
09:25AM
Loading…
09:25AM
Oct-07-24 11:00AM
02:52AM
(Pharmaceutical Technology)
Oct-03-24 09:00AM
04:52AM
(Pharmaceutical Technology)
Oct-02-24 10:43AM
08:30AM
Oct-01-24 06:00PM
Sep-25-24 09:55AM
Sep-24-24 06:00PM
04:06PM
Loading…
Sep-23-24 04:06PM
(Investor's Business Daily)
02:12PM
09:38AM
(Investor's Business Daily)
Sep-21-24 12:00PM
07:36AM
Sep-19-24 09:00AM
Sep-18-24 01:30PM
Sep-17-24 06:00PM
Sep-16-24 06:00AM
01:52AM
Sep-14-24 08:45AM
01:51AM
Sep-13-24 06:55AM
Sep-12-24 06:11PM
04:05PM
(Investor's Business Daily)
01:46PM
Loading…
01:46PM
10:20AM
10:07AM
(The Wall Street Journal)
09:45AM
09:35AM
08:30AM
Sep-11-24 05:50PM
03:52AM
(Pharmaceutical Technology)
Sep-10-24 09:20AM
08:00AM
Sep-08-24 01:57AM
Sep-06-24 09:15AM
Sep-05-24 08:00AM
Sep-04-24 09:25AM
06:52AM
Aug-30-24 05:34PM
02:05PM
01:46AM
Aug-28-24 06:19PM
Aug-27-24 09:15AM
Aug-26-24 01:19PM
Aug-22-24 09:00AM
Aug-21-24 04:05PM
Aug-20-24 02:00PM
09:00AM
08:30AM
Aug-19-24 05:12AM
(Pharmaceutical Technology)
Aug-17-24 01:44AM
Aug-15-24 01:13PM
(Pharmaceutical Technology)
09:09AM
06:53AM
Aug-14-24 05:01PM
01:59PM
Aug-13-24 08:45AM
Aug-10-24 06:50AM
Aug-09-24 04:34PM
04:11PM
(Investor's Business Daily)
02:43PM
12:22PM
(Thomson Reuters StreetEvents)
11:15AM
09:45AM
08:23AM
06:52AM
(Pharmaceutical Technology)
01:12AM
Aug-08-24 09:45PM
06:00PM
05:16PM
(Investor's Business Daily)
05:15PM
04:20PM
(Investor's Business Daily)
04:12PM
04:11PM
(Associated Press Finance)
04:05PM
04:02PM
10:15AM
Aug-07-24 09:01AM
Aug-05-24 09:16AM
Aug-04-24 08:00AM
Aug-03-24 06:45AM
Aug-02-24 03:33PM
09:25AM
Aug-01-24 05:50PM
10:01AM
Jul-31-24 04:30PM
09:00AM
Jul-30-24 06:52AM
Jul-29-24 06:00PM
Jul-25-24 04:05PM
09:15AM
06:15AM
Jul-24-24 04:30AM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Parsey Merdad Chief Medical Officer Oct 01 '24 Sale 83.83 2,000 167,660 100,189 Oct 02 04:58 PM MERDAD V PARSEY Officer Oct 01 '24 Proposed Sale 83.83 2,000 167,660 Oct 01 04:27 PM Parsey Merdad Chief Medical Officer Sep 12 '24 Option Exercise 57.92 25,000 1,448,000 123,435 Sep 13 07:07 PM Parsey Merdad Chief Medical Officer Sep 12 '24 Sale 84.50 21,246 1,795,287 102,189 Sep 13 07:07 PM Mercier Johanna Chief Commercial Officer Sep 12 '24 Sale 83.78 29,357 2,459,577 78,127 Sep 13 05:08 PM MERDAD V PARSEY Officer Sep 12 '24 Proposed Sale 84.50 21,246 1,795,287 Sep 12 04:45 PM JOHANNA MERCIER Officer Sep 12 '24 Proposed Sale 83.78 29,357 2,459,577 Sep 12 04:43 PM Mercier Johanna Chief Commercial Officer Aug 28 '24 Sale 78.03 9,513 742,299 105,466 Aug 29 03:23 PM JOHANNA MERCIER Officer Aug 28 '24 Proposed Sale 78.03 9,513 742,299 Aug 28 04:18 PM Mercier Johanna Chief Commercial Officer Aug 13 '24 Sale 73.98 5,490 406,150 114,979 Aug 14 02:23 PM JOHANNA MERCIER Officer Aug 13 '24 Proposed Sale 73.98 5,490 406,150 Aug 13 04:27 PM Parsey Merdad Chief Medical Officer Jul 01 '24 Sale 68.63 2,000 137,260 96,380 Jul 01 08:06 PM GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Parsey Merdad Chief Medical Officer Apr 01 '24 Sale 72.96 2,000 145,920 96,304 Apr 02 06:38 PM Parsey Merdad Chief Medical Officer Feb 29 '24 Sale 72.74 8,230 598,624 92,706 Feb 29 06:35 PM Parsey Merdad Chief Medical Officer Feb 28 '24 Sale 73.18 2,000 146,360 100,936 Feb 29 06:35 PM GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM GILEAD SCIENCES, INC. 10% Owner Jan 29 '24 Buy 21.00 15,238,095 319,999,995 30,061,124 Jan 31 05:00 PM Dickinson Andrew D Chief Financial Officer Jan 16 '24 Sale 85.78 5,000 428,900 101,534 Jan 17 06:01 PM Mercier Johanna Chief Commercial Officer Jan 09 '24 Sale 85.23 8,242 702,466 82,729 Jan 10 03:58 PM Dickinson Andrew D Chief Financial Officer Oct 17 '23 Sale 80.00 5,000 400,017 104,003 Oct 18 04:31 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite